Floatz logo

Recombinant Ephb4-Hsa Fusion Protein

Stage IIIB Gallbladder Cancer

University of Southern Californiaprotein_peptidePhase 1Active
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
95/ 100

Competitive context

29 Active assets in the Stage IIIB Gallbladder Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Lisata Therapeutics, Inc.
Phase 2BBB
Capecitabine
Merck Sharp & Dohme LLC
Phase 3BB
Eloxatin
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Sevoflurane
Tokyo Medical and Dental University
Phase 4BB
Epirubicin
Merck Sharp & Dohme LLC
Phase 2BB

View all 50 →

Same molecule, other indications

Recombinant Ephb4-Hsa Fusion Protein is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
infiltrating bladder urothelial carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
urothelial carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →